GSK-4336A
Legal status
Legal status
Identifiers
  • 7,9-dichloro-3-oxo-N-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1,4-benzoxazepine-5-carboxamide
PubChem CID
Chemical and physical data
FormulaC17H11Cl2F3N2O3
Molar mass419.18 g·mol−1
3D model (JSmol)
  • C1C(=O)NC(C2=C(O1)C(=CC(=C2)Cl)Cl)C(=O)NC3=CC=C(C=C3)C(F)(F)F
  • InChI=1S/C17H11Cl2F3N2O3/c18-9-5-11-14(24-13(25)7-27-15(11)12(19)6-9)16(26)23-10-3-1-8(2-4-10)17(20,21)22/h1-6,14H,7H2,(H,23,26)(H,24,25)
  • Key:USVVDHAIRZSKRE-UHFFFAOYSA-N

GSK4336A is a drug which acts as a selective androgen receptor modulator (SARM), and was developed for androgen replacement therapy.[1][2]

See also

References

  1. ^ Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT (2008). "Selective androgen receptor modulators in preclinical and clinical development". Nuclear Receptor Signaling. 6: e010. doi:10.1621/nrs.06010. PMC 2602589. PMID 19079612.
  2. ^ Zhang X, Lanter JC, Sui Z (September 2009). "Recent advances in the development of selective androgen receptor modulators". Expert Opinion on Therapeutic Patents. 19 (9): 1239–1258. doi:10.1517/13543770902994397. PMID 19505196. S2CID 46186955.
Categories